The research company Aptahem's CEO Mikael Lindstam describes 2026 as a year of opportunities with a focus on a possible establishment in the USA, deeper partner dialogues, and preparations for a Phase 2 study. At the same time, the company will continue to manage resources with great prudence.According to the CEO, Aptahem is entering 2026 better positioned than a year ago.On January 1, Aptahem moves into Medeon Science Park in Malmö, which suits the company given its current focus. During the year, Aptahem has adapted financial and regulatory materials to IFRS, held working meetings in the USA, and taken preparatory steps in FDA processes. "Perhaps the most significant step in 2025 was therefore that we began our strategic work to potentially establish Aptahem in the US capital market, with the goal of raising capital for the necessary Phase 2 study, increasing liquidity in the share, and creating long-term access to specialized life science investors," writes Lindstam.